Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia.

First Department of Internal Medicine, School of Medicine, University of Athens, Laiko Hospital, Athens, Greece.
The Annals of thoracic surgery (Impact Factor: 3.45). 07/2006; 81(6):2037-43. DOI: 10.1016/j.athoracsur.2006.01.026
Source: PubMed

ABSTRACT Thalassemia intermedia has a later clinical onset and a milder anemia than thalassemia major, characterized by high output state, left ventricle remodeling, and age-related pulmonary hypertension. Bone deformities, extramedullary hematopoiesis (EMH), and spleen and liver enlargement are the consequences of hypoxia and enhanced erythropoiesis. The EMH-related pleural effusion is rarely referred to in the literature of thalassemia.
We reviewed the thalassemia patients' medical records hospitalized for pleural effusion in our Department, within the last 6 years.
Eight (4 men) thalassemia intermedia patients admitted for symptomatic pleural effusion were identified. Common clinical findings on admission were dyspnea and apyrexia. Their mean hemoglobin level was 7.15 +/- 0.64 g/dL. Radiology revealed intrathoracic EMH and pleural effusion in all patients: exudative in seven patients and massive hemothorax in one. Cytologic fluid analysis was negative for malignancy. Fluid and serum cultures, antibodies, and stains were negative for viral, bacterial, and fungal infection. The hemothorax case was successfully treated with repeated aspirations, transfusions, and hydroxyurea. Although repeated thoracentesis and radiation could not control the effusions in the rest of the cases, pleurodesis was successful in 5 patients, without serious adverse events. Treatment was further accomplished with hydroxyurea. No relapses were observed in the mean 30 month follow-up period.
Afebrile, EMH-related pleuritis represents a potentially life-threatening complication in thalassemia. Therapy should be individualized and treatment is emerging. Pleurodesis seems to be an effective and safe therapeutic option for exudative effusions, while transfusion-chelation therapy combined with hydroxyurea may be helpful in suppressing increased erythropoiesis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Extramedullary haemopoiesis (EMH) is a complication commonly associated with beta-thalassaemia intermedia; it is frequently asymptomatic but can sometimes lead to symptomatic tumour-like masses. No guidelines or common consensus are available in literature regarding the different treatment strategies and only single cases have been reported. We describe a case of spinal cord compression due to intrathoracic EMH masses treated with combined radiotherapy and hydroxyurea.
    Internal Medicine Journal 04/2014; 44(4):409-12. · 1.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extramedullary hematopoiesis (EMH) is a rare disease that is characterized by the presence of hemopoietic tissue outside the bone marrow. The masses that form are usually microscopic and asymptomatic, but occasionally lead to tumor-like masses. A 56-year-old male who initially presented to the First Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China) with upper abdominal pain and jaundice was found to have paravertebral masses in the thorax. Histopathological examination of a computed tomography-guided needle aspiration biopsy of the masses revealed EMH. The current study presents this unusual case, in which EMH was diagnosed by chance in a patient with hereditary spherocytosis. As the intrathoracic EMH was asymptomatic, the patient was discharged with the proviso of regular follow-up examinations. The patient exhibited improved blood cell counts following a splenectomy to reduce the hemolysis and stabilize the thoracic masses. The thoracic masses have been closely followed for one and a half years. A correct diagnosis can thus aid in avoiding unnecessary surgical intervention, particularly in an asymptomatic patient.
    Oncology letters 06/2014; 7(6):1984-1986. · 0.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Beta-thalassemia is due to a defect in the synthesis of the beta-globin chains, leading to alpha/beta imbalance, ineffective erythropoiesis, and chronic anemia. The spectrum of thalassemias is wide, with one end comprising thalassemia minor, which consists of a mild hypochromic microcytic anemia with no obvious clinical manifestations, while on the other end is thalassemia major, characterized by patients who present in their first years of life with profound anemia and regular transfusion requirements for survival. Along the spectrum lies thalassemia intermedia, a term developed to describe patients with manifestations that are neither mild enough nor severe enough to be classified in the spectrum's extremes. Over the past decade, our understanding of β-thalassemia intermedia has increased tremendously with regards to molecular information as well as pathophysiology. It is now clear that β-thalassemia intermedia has a clinical presentation as well as complications associated with the disease that are different from those of β-thalassemia major. This review is designed to tackle issues related to β-thalassemia intermedia from the basic definition of the disease to paramedical issues, namely the quality of life in these patients. Genetics and pathophysiology are revisited, as well as the complications specific to this disease. These complications include effects on several organ systems, including the cardiovascular, hepatic, endocrine, renal, brain, and skeletal systems. Extramedullary hematopoiesis is also discussed in this article. Risk factors are highlighted and cutoffs are identified to minimize morbidities in β-thalassemia intermedia. Several treatment modalities are considered by shining a light on the pros and cons of each modality, as well as the role of special pharmacological agents in the progress of the disease and its morbidities. Finally, health-related quality of life is discussed in these patients with a direct comparison to the more severe β-thalassemia major.
    Turkish Journal of Haematology 03/2014; 31(1):5-16. · 0.34 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014